EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bioporto AS's Enterprise Value is €68.34 Mil.
Bioporto AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.51 Mil. Therefore, Bioporto AS's EV-to-FCF for today is -6.50.
The historical rank and industry rank for Bioporto AS's EV-to-FCF or its related term are showing as below:
FRA:2P4'
s EV-to-FCF Range Over the Past 10 Years
Min: -35.86 Med: -10.96 Max: -4.48
Current: -6.37
During the past 13 years, the highest EV-to-FCF of Bioporto AS was -4.48. The lowest was -35.86. And the median was -10.96.
FRA:2P4's EV-to-FCF is ranked worse than 100% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.85
vs FRA:2P4: -6.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioporto AS's PE Ratio (TTM) for today is calculated as:
Bioporto AS's share price for today is €0.1295.
Bioporto AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.024.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bioporto AS EV-to-FCF Related Terms
Bioporto AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bioporto AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Bioporto AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bioporto AS's EV-to-FCF falls into.
Bioporto AS's current Enterprise Value is €68.34 Mil.
Bioporto AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (FRA:2P4) has a EV-to-FCF of -6.50 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry.
Is Bioporto AS's EV-to-FCF too high?
Bioporto AS's current EV-to-FCF is -6.50. Based on the distribution chart, Bioporto AS ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bioporto AS has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #999999 out of 97 companies for EV-to-FCF. This places Bioporto AS in the lower half of its industry. The industry median EV-to-FCF is 22.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.85, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current EV-to-FCF is -6.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (FRA:2P4) has a current EV-to-FCF of -6.50. The stock's GF Value™ is €0.15, compared to a current price of €0.13 — trading 13.7% below its estimated fair value. The current EV-to-FCF is -6.50. Bioporto AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bioporto AS (FRA:2P4), the current EV-to-FCF is -6.50 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (FRA:2P4) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of €0.13 is trading 13.7% below its estimated GF Value™ of €0.15.
Key valuation signals for FRA:2P4:
EV-to-FCF: -6.50
GF Value™: €0.15 vs. price of €0.13 (13.7% below fair value)
No single metric tells the full story. See the FRA:2P4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score
Get the complete analysis for FRA:2P4
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2P4 has been successfully added to your 
